Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Efficacy of QA102 in Subjects With Dry Age-Related Macular Degeneration (AMD)

NCT05536752 is registered in ClinicalTrials.gov with Smilebiotek Zhuhai Limited as lead sponsor.

NCT NCT05536752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05536752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Efficacy of QA102 in Subjects With Dry Age-Related Macular Degeneration (AMD)
Lead sponsor
Smilebiotek Zhuhai Limited
Phase
Phase 2
Overall status
Completed
Start date
September 22, 2022
Completion date
November 12, 2024
Enrollment
150 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

dry age-related macular degeneration